Clinical Trial Update: First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating first-line RC48 (disitamab vedotin) in combination with tislelizumab and S-1 for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Disitamab Vedotin (RC48) (disitamab vedotin)
• S-1 (tegafur/gimeracil/oteracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING